Pharmaceuticals, Biotechnology and Life Sciences
GW Pharmaceuticals paved a way to launch Epidyolex in Europe, for use as adjunctive therapy of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients 2 years of age and older.
GW Pharmaceuticals, a biopharmaceutical company focused on making and selling therapeutics from its cannabinoid product platform, said Monday that the…
GW Pharmaceuticals and its U.S. subsidiary Greenwich Biosciences, have conducted a study which showed the potential of cannabidiol in reducing…
A study showed that cannabidiol shows great promise in that it may reduce seizures that are otherwise difficult to control.
In the United States, this market’s massive growth potential is being recognized as new states legalize marijuana for medical or recreational use. Industry experts forecast the U.S. cannabis market rounding $7 billion in 2016, while the annual sale of state-legal cannabis products is forecast to exceed $20 billion by 2020.